. Hemoglobin-δ-Gluconolactone (δ-Glu) assay. Treatments Inhibition of HbA1c (%) Hb + δ-Gluconolactone + AG 45.89 ± 1.14 a Hb + δ-Gluconolactone + ZnO-NPs 1 mg 1.81 ± 0.87 d 2.5 mg 13.97 ± 1.30 c 5 mg 26.54 ± 1.21 b Hb+ δ-Gluconolactone + Zinc Nanopowder 1 mg 0.27 ± 0.48 d 2.5 mg 0.53 ± 0.86 d 5 mg 1.13 ± 0.97 d
. Hemoglobin-δ-Gluconolactone (δ-Glu) assay. Values are means of three independent replicates (n = 3) and ± indicate standard errors. Means followed by the same letter(s) within the same column are not significantly (p < 0.05) different according to Tukey's HSD. Values are means of three independent replicates (n = 3) and ± indicate standard errors. Means followed by the same letter(s) within the same column are not significantly (p < 0.05) different according to Tukey's HSD. Table S3 . N-Acetylglycyl-lysine methyl ester (G.K.) peptide mediated ribose glycation with and without treatment. Values are means of three independent replicates (n = 3) and ± indicate standard errors. Means followed by the same letter(s) within the same column are not significantly (p < 0.05) different according to Tukey's HSD.
